10x Insights
Loading account…
COR

Cencora

Health CareWholesaleS&P 500
Ticker CORCONSHOHOCKEN, PAFiscal year ends SeptemberBook value per share $15.66Diluted shares 194.9M

Cencora, Inc. is one of the largest global pharmaceutical sourcing and distribution services companies, operating through its website at www.cencora.com. The company helps healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care by delivering… From the company’s description.

Fiscal year 2025 · ends 09-30Changes are against fiscal 2024The amber dot is the latest twelve months, to 2026-06-30
Sales & profitability
$321.33BFY2025
+9.3% year over year
Last 12 mo $332.77B
0.82%FY2025
+0.1 percentage points
Last 12 mo 0.91%
$1.57BFY2025
+3.2% year over year
Last 12 mo $2.64B
146.95%FY2025
−163.2 percentage points
Last 12 mo 86.03%
Cash & financing
$3.88BFY2025
+11.2% year over year
Last 12 mo $4.82B
$3.21BFY2025
+7.0% year over year
Last 12 mo $4.06B
5.08FY2025
Was 6.79× a year earlier
Last 12 mo 3.84
195.2MFY2025
−2.5% year over year
Last 12 mo 194.9M

Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.

What Cencora does

In the company’s own words

Cencora, Inc. is one of the largest global pharmaceutical sourcing and distribution services companies, operating through its website at www.cencora.com. The company helps healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care by delivering innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.

Cencora operates through two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care facilities, physician practices, medical and dialysis clinics, and veterinarians. This segment also provides specialty pharmaceutical distribution including plasma and blood products, injectable pharmaceuticals, vaccines, and other specialty products to physicians specializing in oncology and retina care. The International Healthcare Solutions segment focuses on international pharmaceutical wholesale and related service operations and global commercialization services, distributing pharmaceuticals and healthcare products primarily in Europe, serving as a leading global specialty transportation and logistics provider for the biopharmaceutical industry, and providing specialized services including regulatory affairs, market access, pharmacovigilance, and quality management and compliance for the life sciences industry.

As of September 30, 2025, Cencora employed more than 51,000 employees globally, with approximately 47,000 full-time employees and approximately 41 percent based in the United States. The company operates a geographically diverse network of distribution service centers and other operations in the United States and select global markets. Cencora's top ten customers, including governmental agencies and group purchasing organizations, represented approximately 66 percent of revenue in fiscal 2025, with Walgreens and Boots together accounting for approximately 25 percent of revenue and Evernorth Health Services accounting for approximately 13 percent of revenue. The company maintains strong supplier relationships, with the ten largest suppliers accounting for approximately 57 percent of purchases in fiscal 2025.

Company details
Sector
Health Care
Industry (SIC)
Wholesale
Headquarters
CONSHOHOCKEN, PA
Fiscal year end
September
CIK
1140859
SIC
5122

Financial performance, year by year

Fiscal 2013–2025 · USD
$-37.02B$63.83B$164.69B$265.54B$366.39B2013201420152016201720182019202020212022202320242025Last 12 moLast 12 monthsLast 12 months

The full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.

Ownership

Who owns Cencora — and what changed

Funds as of 2026Q2 · superinvestors as of 2026-06-30

938
funds hold it
0 of 35
superinvestors hold it
$23.98B
held by funds, at market
43.9%
of shares held by funds
16
bond issues held by funds

Largest fund holders · Cencora’s weight in each

VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.07%of fund net assets
VANGUARD 500 INDEX FUND
VOO · VANGUARD INDEX FUNDS
0.09%of fund net assets
T. Rowe Price Capital Appreciation Fund
PRWCX · T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
1.78%of fund net assets
VANGUARD MID-CAP INDEX FUND
VO · VANGUARD INDEX FUNDS
0.51%of fund net assets
VANGUARD HEALTH CARE FUND
VGHCX · VANGUARD SPECIALIZED FUNDS
—of fund net assets

Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.

Cencora’s bonds, as funds hold them

Funds report holding 16 issues of Cencora’s debt, $1.50B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.19%, maturing 2027 to 2056.

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.

Connected research

Put this business in context.

Compare this company with peers, find it in your funds and follow its financial history with your connected AI:

  • “How do Cencora and its peers compare on margins and cash generation over ten years?”
  • “Where did five years of Cencora's earnings go — cash, debt, buybacks, reinvestment?”
  • “What changed in Cencora's last four quarterly filings that the numbers alone won't show?”
See how it works →All research tools with a subscription. Use your own AI account.